NASDAQ:EMBC Embecta (EMBC) Stock Price, News & Analysis $15.57 -0.30 (-1.89%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$15.42▼$16.0950-Day Range$11.46▼$16.3552-Week Range$9.93▼$23.75Volume428,768 shsAverage Volume427,875 shsMarket Capitalization$897.92 millionP/E Ratio12.87Dividend Yield3.85%Price Target$12.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Embecta alerts: Email Address Embecta MarketRank™ Stock AnalysisAnalyst RatingReduce1.50 Rating ScoreUpside/Downside22.9% Downside$12.00 Price TargetShort InterestBearish5.42% of Float Sold ShortDividend StrengthStrongBased on Four FactorsSustainabilityN/ANews Sentiment0.48Based on 8 Articles This WeekInsider TradingN/AProj. Earnings Growth-2.62%From $2.29 to $2.23 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.74 out of 5 starsMedical Sector864th out of 936 stocksSurgical & Medical Instruments Industry94th out of 101 stocks 0.8 Analyst's Opinion Consensus RatingEmbecta has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageEmbecta has only been the subject of 1 research reports in the past 90 days.Read more about Embecta's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.42% of the float of Embecta has been sold short.Short Interest Ratio / Days to CoverEmbecta has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in Embecta has recently increased by 7.33%, indicating that investor sentiment is decreasing significantly. Previous Next 3.3 Dividend Strength Dividend LeadershipEmbecta is a leading dividend payer. It pays a dividend yield of 3.67%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthEmbecta does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Embecta is 49.59%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Embecta will have a dividend payout ratio of 26.91% next year. This indicates that Embecta will be able to sustain or increase its dividend.Read more about Embecta's dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EMBC. Previous Next 2.5 News and Social Media Coverage News SentimentEmbecta has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Embecta this week, compared to 2 articles on an average week.Search Interest1 people have searched for EMBC on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Embecta to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Embecta insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.28% of the stock of Embecta is held by insiders.Percentage Held by Institutions93.83% of the stock of Embecta is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Embecta's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Embecta are expected to decrease by -2.62% in the coming year, from $2.29 to $2.23 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Embecta is 12.87, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 143.45.Price to Earnings Ratio vs. SectorThe P/E ratio of Embecta is 12.87, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 164.48.Read more about Embecta's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Embecta Stock (NASDAQ:EMBC)Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.Read More EMBC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EMBC Stock News HeadlinesJuly 22, 2024 | markets.businessinsider.comBTIG Remains a Hold on Embecta Corporation (EMBC)July 22, 2024 | msn.comDiabetes device maker Embecta exploring sale - FTJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 18, 2024 | globenewswire.comembecta to Report Fiscal Third Quarter 2024 Financial ResultsJuly 16, 2024 | americanbankingnews.comEmbecta (NASDAQ:EMBC) PT Lowered to $12.00 at Morgan StanleyJuly 11, 2024 | seekingalpha.comFundamentals Are The Key For Investors Considering Embecta StockJune 24, 2024 | globenewswire.comembecta-sponsored Abstracts Presented at American Diabetes Association's 84th Scientific Sessions Highlight Unmet Need for Patch Pumps with 300u Insulin ReservoirJune 20, 2024 | prnewswire.comZimmer Biomet Announces Appointment of Devdatt Kurdikar to Board of DirectorsJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.May 21, 2024 | investorplace.comTrade Winds Turning: 3 Stocks Poised to Gain from Biden's China TariffsMay 13, 2024 | finance.yahoo.comEmbecta Corp. (NASDAQ:EMBC) Q2 2024 Earnings Call TranscriptMay 13, 2024 | seekingalpha.comEmbecta Corp. (EMBC) Q2 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comEmbecta Corp (EMBC) Surpasses Analyst Revenue Forecasts in Q2 Fiscal 2024May 10, 2024 | finance.yahoo.comEmbecta Second Quarter 2024 Earnings: Beats ExpectationsMay 9, 2024 | marketwatch.comEmbecta Shares Rise After 2Q Results, Higher FY GuidanceMay 9, 2024 | globenewswire.comEmbecta Corp. Reports Second Quarter Fiscal 2024 Financial ResultsMay 9, 2024 | globenewswire.comembecta Announces Quarterly Cash DividendMay 8, 2024 | markets.businessinsider.comEmbecta earnings preview: what Wall Street is expectingSee More Headlines Receive EMBC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Embecta and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Ex-Dividend for 6/14 Dividend5/24/2024Dividend Payable6/14/2024Today7/26/2024Next Earnings (Confirmed)8/09/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:EMBC CUSIPN/A CIK1872789 Webwww.embecta.com Phone201-847-6880FaxN/AEmployees2,200Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$12.00 Low Stock Price Target$12.00 Potential Upside/Downside-22.9%Consensus RatingReduce Rating Score (0-4)1.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$1.21 Trailing P/E Ratio12.87 Forward P/E Ratio6.80 P/E GrowthN/ANet Income$70.40 million Net Margins6.20% Pretax Margin4.35% Return on Equity-18.42% Return on Assets12.05% Debt Debt-to-Equity RatioN/A Current Ratio2.29 Quick Ratio1.79 Sales & Book Value Annual Sales$1.12 billion Price / Sales0.80 Cash Flow$3.51 per share Price / Cash Flow4.43 Book Value($14.34) per share Price / Book-1.09Miscellaneous Outstanding Shares57,670,000Free Float57,509,000Market Cap$897.92 million OptionableOptionable Beta0.99 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Devdatt Kurdikar (Age 56)President, CEO & Director Comp: $2.2MMr. Jacob P. Elguicze (Age 51)Senior VP & CFO Comp: $1.05MMr. Brian R. Capone (Age 49)VP, Chief Accounting Officer & Corporate Controller Comp: $645.16kMr. Jeffrey Z. Mann (Age 52)Senior VP, General Counsel, Head of Business Development & Corporate Secretary Comp: $959.45kMr. Shaun Curtis (Age 55)Senior Vice President of Global Manufacturing & Supply Chain Comp: $915.67kMs. Colleen Riley (Age 60)Senior VP & Chief Technology Officer Mr. Pravesh KhandelwalVP & Head of Investor RelationsMs. Ginny BlockiSenior Vice President of Global Marketing & Product ManagementMs. Jean M. Casner (Age 66)Senior VP & Chief Human Resources Officer Mr. Tom Blount (Age 50)Senior VP & President of North America More ExecutivesKey CompetitorsICU MedicalNASDAQ:ICUITandem Diabetes CareNASDAQ:TNDMIntegra LifeSciencesNASDAQ:IARTUFP TechnologiesNASDAQ:UFPTNovoCureNASDAQ:NVCRView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 12,424 shares on 7/26/2024Ownership: 1.376%AlphaCentric Advisors LLCSold 55,000 shares on 7/26/2024Ownership: 0.098%Allspring Global Investments Holdings LLCSold 10,210 shares on 7/26/2024Ownership: 0.025%SummerHaven Investment Management LLCBought 1,179 shares on 7/24/2024Ownership: 0.063%Nisa Investment Advisors LLCBought 4,287 shares on 7/20/2024Ownership: 0.046%View All Insider TransactionsView All Institutional Transactions EMBC Stock Analysis - Frequently Asked Questions How have EMBC shares performed this year? Embecta's stock was trading at $18.93 at the beginning of 2024. Since then, EMBC stock has decreased by 17.7% and is now trading at $15.57. View the best growth stocks for 2024 here. How were Embecta's earnings last quarter? Embecta Corp. (NASDAQ:EMBC) posted its earnings results on Thursday, May, 9th. The company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.43 by $0.24. The business's revenue was up 3.6% compared to the same quarter last year. Who are Embecta's major shareholders? Top institutional shareholders of Embecta include Bank of New York Mellon Corp (1.38%), Raymond James & Associates (0.34%), AlphaCentric Advisors LLC (0.10%) and SummerHaven Investment Management LLC (0.06%). Insiders that own company stock include Devdatt Kurdikar, Jacob Elguicze, Jeffrey Z Mann and David F Melcher. View institutional ownership trends. How do I buy shares of Embecta? Shares of EMBC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:EMBC) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Embecta Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Embecta With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
